ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer

Feng, Yuanfa; Deng, Yulin; Tang, Zhenfeng; Cai, Shanghua; Li, Jinchuang; Liu, Ren; Wan, Jiaming; He, Huichan; Zeng, Guohua; Ye, Jianheng*; Han, Zhaodong*; Zhong, Weide*广州医学院; 南方医科大学; 1
Frontiers in Endocrinology2023-3-16DOI: 10.3389/fendo.2023.1148898
1被引7阅读
引用收藏
分享

摘要

BackgroundEnzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for predicting progression and relapse-free survival (RFS) in PCa. MethodsEnzalutamide-induced candidate markers were derived from single-cell RNA sequencing analysis integrating three enzalutamide-stimulated models (0-, 48-, and 168-h enzalutamide stimulation). ENZ-sig was constructed on the basis of candidate genes that were associated with RFS in The Cancer Genome Atlas leveraging least absolute shrinkage and selection operator method. The ENZ-sig was further validated in GSE70768, GSE94767, E-MTAB-6128, DFKZ, GSE21034, and GSE70769 datasets. Biological enrichment analysis was used to discover the underlying mechanism between high ENZ-sig and low ENZ-sig in single-cell RNA sequencing and bulk RNA sequencing. ResultsWe identified a heterogenous subgroup that induced by enzalutamide stimulation and found 53 enzalutamide-induced candidate markers that are related to trajectory progression and enzalutamide-stimulated. The candidate genes were further narrowed down into 10 genes that are related to RFS in PCa. A 10-gene prognostic model (ENZ-sig)-IFRD1, COL5A2, TUBA1A, CFAP69, TMEM388, ACPP, MANEA, FOSB, SH3BGRL, and ST7-was constructed for the prediction of RFS in PCa. The effective and robust predictability of ENZ-sig was verified in six independent datasets. Biological enrichment analysis revealed that differentially expressed genes in high ENZ-sig were more activated in cell cycle-related pathway. High-ENZ-sig patients were more sensitive to cell cycle-targeted drugs (MK-1775, AZD7762, and MK-8776) than low-ENZ-sig patients in PCa. ConclusionsOur results provided evidence and insight on the potential utility of ENZ-sig in PCa prognosis and combination therapy strategy of enzalutamide and cell cycle-targeted compounds in treating PCa.

学科与关键词

关键词
prostate cancerenzalutamiderelapse-free survivalsignatureendocrine therapy
相关
加载中…
  • Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
    Marcus Moses; Alex Niu; Michael B. Lilly; Andrew W Hahn; Roberto Nussenzveig; Elisa Ledet; Charlotte Manogue; Patrick Cotogno; Brian Lewis; Jodi Layton; Neeraj Agarwal; Oliver Sartor; Pedro C. BarataCancer Treatment and Research Communications, 2020, 100193.
  • IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
  • Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing
    Zhu, Weian; Huang, Jiongduan; Wu, Jianjie; Wu, Chenglun; Ye, Fengxi; Li, Xiang*; Lai, Wenjie*Heliyon, 2023, 9(11): e21174.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2023-03-16
卷期
第 14 卷
页码
1148898
DOI
10.3389/fendo.2023.1148898
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82072813]; Science and Technology Projects in Guangzhou [202201010726]; Science and Technology Development Fund of Macau [SAR 0031/2021/A]; Emergency Key Program of Guangzhou Laboratory [EKPG21-04]; Guangdong Basic and Applied Basic Research Foundation [2020A1515110792, 2022A1515010342, 2022A1515110245]

作者

  • F

    Feng, Yuanfa (第一作者)

    1 · guangzhou med univ

  • D

    Deng, Yulin

    1 · guangzhou med univ

查看全部 12 位作者收起作者
  • T

    Tang, Zhenfeng

    1 · guangzhou med univ

  • C

    Cai, Shanghua

    guangzhou med univ · 1

  • L

    Li, Jinchuang

    1

  • L

    Liu, Ren

    southern med univ

  • W

    Wan, Jiaming

    1

  • H

    He, Huichan

    1 · guangzhou med univ

  • Z

    Zeng, Guohua

    1 · guangzhou med univ

  • Y

    Ye, Jianheng (通讯)

    1

  • H

    Han, Zhaodong (通讯)

    1

  • Z

    Zhong, Weide (通讯)

    southern med univ · 1 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417